Hypertrophic cardiomyopathy

PACE - Pacing and Clinical Electrophysiology

Volumn 32, Issue SUPPL. 2, 2009, Pages

  Towbin, Jeffrey A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Echocardiography; Electrophysiology clinical; Hemodynamics; Pathology; Pediatrics

Indexed keywords

ADENYLATE KINASE; ATENOLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; ENALAPRIL; LOSARTAN; PROPRANOLOL; VERAPAMIL;

CLINICAL FEATURE; DANON DISEASE; DEFIBRILLATOR; DIASTOLIC DYSFUNCTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ECHOCARDIOGRAPHY; EXERCISE TEST; FABRY DISEASE; GENE IDENTIFICATION; GENOTYPE; GLYCOGEN STORAGE DISEASE TYPE 2; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTFLOW TRACT OBSTRUCTION; HEART PACING; HEREDITY; HISTOPATHOLOGY; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; KEARNS SAYRE SYNDROME; MORPHOLOGY; MYOMECTOMY; PHENOTYPE; REVIEW; SYSTOLIC DYSFUNCTION;

ADOLESCENT; ADULT; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; CHILD, PRESCHOOL; DEATH, SUDDEN, CARDIAC; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 68249149715     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2009.02381.x     Document Type: Review

References (110)

1. Maron BJ. Hypertrophic cardiomyopathy: A systemic review. JAMA 2002 287 : 1308 1320.
2. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004 363 : 188 189.
3. Ommen SR, Nishimura RA. Hypertrophic cardiomyopathy. Curr Probl Cardiol 2004 29 : 239 291.
4. McKenna WJ, Behr ER. Hypertrophic cardiomyopathy: Management, risk stratification, and prevention of sudden death. Heart 2002 87 : 169 176.
5. Frenneaux MP. Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. Heart 2004 90 : 570 575.
6. Maron BJ, Carney KP, Lever HM, Lewis JF, Barac I, Casey SA, Sherrid MV. Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003 41 : 974 980.
7. Maron BJ. Hypertrophic cardiomyopathy and sudden death: New perspective on risk stratification and prevention with the implantable cardioverter- defibrillator. Eur Heart J 2000 21 : 1979 1983.
8. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilation in hypertrophic cardiomyopathy. Am J Cardiol 1987 60 : 123 139.
9. Aurigemma GP, Gaasch WH. Diastolic heart failure. N Engl J Med 2004 351 : 1097 1105.
10. Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med 2004 55 : 373 394.
11. Towbin JA, Lipshultz SE. 1999. Genetics of neonatal cardiomyopathy. Curr Opin Cardiol 14 : 250 262.
12. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. 1995. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 411 subjects in the CARDIA study. Circulation 92 : 785 789.
13. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part I. Diagnosis, prognosis, and measurements of diastolic function. Circulation 2002 105 : 1387 1393.
14. Redfield MM, Jacobsen SJ, Burnett JC Jr., Mahoney DW, Barley KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003 289 : 194 202.
15. Vulpian A. Contribution à l'étude des rétré cissements de l'orifice ventriculo-aortique. Arch Physiol 1868 3 : 220 222.
16. Watkins H. Genetic clues to disease pathways in hypertrophic and dilated cardiomyopathies. Circulation 2003 107 : 1344 1346.
17. Moolman JC, Corfield VA, Posen G, Ngumbela K, Seidman C, Brink PA, Watkins H. Sudden death due to troponin T mutations. J Am Coll Cardiol 1997 29 : 549 555.
18. Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O'Donoghue A, Spirito P, et al. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995 332 : 1058 1064.
19. Kimura A, Harada H, Park JE, Nishi H, Satoh M, Takahashi M, Hiroi S, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 1997 16 : 379 382.
20. Olson TM, Doan TP, Kishimoto NY, Whitby FG, Ackerman MJ, Fananapazir L. Inherited and de novo mutations in the cardiac actin gene cause hypertrophic cardiomyopathy. J Mol Cell Cardiol 2000 32 : 1687 1694.
21. Poetter K, Jiang H, Hassanzadeh S, Master SR, Chang A, Dalakas MC, Rayment I, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 1996 13 : 63 69.
22. Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW, Quinones MA, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 2001 104 : 128 130.
23. Nagueh SF, Kopelen HA, Lim DS, Zoghbi WA, Quinones MA, Roberts R, Marian AJ. Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2000 102 : 1346 1350.
24. McMahon CJ, Nagueh SF, Pignatelli RH, Denfield SW, Dreyer WJ, Price JF, Clunie S, et al. Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 109 : 1756 1762.
25. Pignatelli RH, McMahon CJ, Dreyer WJ, Denfield SW, Price J, Belmont JW, Craigen WJ, et al. Clinical characterization of left ventricular noncompaction in children. A relatively common form of cardiomyopathy. Circulation 2003 108 : 2672 2678.
26. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, Ahmad F, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001 344 : 1823 1831.
27. Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, Salmon A, et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: Evidence for a central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001 10 : 1215 1220.
28. Rivenes SM, Towbin JA, Gajarski RJ, Price JK, Denfield SW. Sudden death and cardiovascular collapse in children with restrictive cardiomyopathies. Circulation 2000 102 : 876 882.
29. Denfield SW. Sudden death in children with restrictive cardiomyopathy. Card Electrophysiol Rev 2002 6 : 163 167.
30. Cetta F, O'Leary PW, Seward JB, Driscoll DJ. Idiopathic restrictive cardiomyopathy in childhood: Diagnostic features and clinical course. Mayo Clin Proc 1995 70 : 634 640.
31. Lewis AB. Clinical profile and outcome of restrictive cardiomyopathy in children. Am Heart J 1992 123 : 1589 1593.
32. Arad M, Benson DW, Perez-Atayde AR, McKenna WJ, Sparks EA, Kanter RJ, McGarry K, et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 2002 107 : 357 362.
33. Wang X, Osinska H, Gerdes AM, Robbins J. Desmin filaments and cardiac disease: Establishing causality. J Card Fail 2002 8 : S287 S292.
34. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, Kristinsson A, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998 338 : 1248 1257.
35. Vikstrom KL, Leinwand LA. Contractile protein mutations and heart disease. Curr Opin Cell Biol 1996 8 : 97 105.
36. Watkins H, Rosenweig A, Hwang DS, Levi T, McKenna W, Seidman CE, Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992 326 : 1108 1114.
37. Van Driest SL, Ackerman MJ, Ommen SR, Shakur R, Will ML, Nishimura RA, Tajik AJ, et al. Prevalence and severity of "benign" mutations in the β-myosin heavy chain, cardiac troponin T, and α-tropomyosin genes in hypertrophic cardiomyopathy. Circulation 2002 106 : 3085 3090.
38. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004 350 : 1953 1959.
39. Jarcho JA, McKenna W, Pare JA, Solomon SD, Holcombe RF, Dickie S, Levi T, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 1989 321 : 1372 1378.
40. Solomon SD, Jarcho JA, McKenna WJ, Geisterfer-Lowrance A, Germain R, Salerni R, Seidman JG, et al. Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease. J Clin Invest 1990 86 : 993 999.
41. Watkins H, MacRae C, Thierfelder L, Chou YH, Frenneaux M, McKenna W, Seidman JG, et al. A disease locus for familial hypertrophic cardiomyopathy maps to chromosome 1q3. Nat Genet 1993 3 : 333 337. (Pubitemid 23112959)
42. Thierfelder L, MacRae C, Watkins H, Tomfohrde J, Williams M, McKenna W, Bohm K, et al. A familial hypertrophic cardiomyopathy locus maps to chromosome 15q2. Proc Natl Acad Sci USA 1993 90 : 6270 6274.
43. Carrier L, Hengstenberg C, Beckmann JS, Guicheney P, Dufour C, Bercovici J, Dausse E, et al. Mapping of a novel gene for familial hypertrophic cardiomyopathy to chromosome 11. Nat Genet 1993 4 : 311 313.
44. MacRae CA, Ghaisas N, Kass S, Donnelly S, Basson CT, Watkins HC, Anan R, et al. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White Syndrome maps to a locus on chromosome 7q3. J Clin Invest 1995 96 : 1216 1220.
45. Poetter K, Jiang H, Hassanzadeh S, Master SR, Chang A, Dalakas MC, Rayment I, et al. Mutation in either the essential regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 1996 13 : 63 69.
46. Kimura A, Harada H, Park JE, Nishi H, Satoh M, Takahashi M, Hiroi S, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet 1997 16 : 379 382.
47. Mogensen J, Klausen IC, Pederson AK, Egeblad H, Bross P, Kruse TA, Gregersen N, et al. α-Cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999 103 : R39 R43.
48. Satoh M, Takahashi M, Sakamoto T, Hiroe M, Marumo F, Kimura A. Structural analysis of the titin gene in hypertrophic cardiomyopathy: Identification of a novel disease gene. Biochem Biophys Res Commun 1999 2625 : 411 417.
49. Geier C, Perrot A, Ozcelik C, Binner P, Counsell D, Hoffmann K, Pilz B, et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation 2003 107 : 1390 1395.
50. Mohiddin SA, Ahmed ZM, Griffith AJ, Tripodi D, Friedman TB, Fananapazir L, Morrell RJ. Novel association of hypertrophic cardiomyopathy, sensorineural deafness and a mutation in unconventional myosin VI (MYO6). J Med Genet 2004 41 : 309 314.
51. Hayashi T, Armimura T, Ueda K, Shibata H, Hohda S, Takahashi M, Hori H, et al. Identification and functional and of caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun 2004 313 : 178 184.
52. Seidman JG, Seidman C. The genetic basis for cardiomyopathy from mutation identification to mechanistic paradigms. Cell 2001 108 : 557 567.
53. Towbin JA, Bowles NE. The failing heart. Nature 2002 415 : 227 233.
54. Schiaffiino S, Reggiani C. Molecular diversity of myofibrillar proteins: Gene regulation and functional significant. Physiol Rev 1996 76 : 371 423.
55. Watkins H, Rosenzweig T, Hwang DS, Levi T, McKenna W, Seidman CE, Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992 326 : 1108 1114.
56. Moolman JC, Corfield VA, Posen B, Ngumbela K, Seidman C, Brink PA, Watkins H. Sudden death due to troponin T mutations. J Am Coll Cardiol 1997 29 : 549 555.
57. Nakajima-Taniguchi C, Matsui H, Fujio Y, Nagata S, Kishimoto T, Yamauchi-Takihara K. Novel missense mutation in cardiac troponin T gene found in Japanese patient with hypertrophic cardiomyopathy. J Mol Cell Cardiol 1997 29 : 839 843.
58. Bonne G, Carrier L, Bercovici J, Cruaud C, Richard P, Hainque B, Gautel M, et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat Genet 1995 11 : 438 440.
59. Watkins H, Conner D, Thierfelder L, Jarcho JA, MacRae C, McKenna WJ, Maron BJ, et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995 11 : 434 437.
60. Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W, Kristinsson A, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998 338 : 1248 1257.
61. Charron P, Dubourg O, Desnos M, Bennaceur M, Carrier L, Camproux AC, Isnard R, et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to cardiac myosin-binding protein C gene. Circulation 1998 97 : 2230 2236.
62. Yoneya K, Okamoto H, Machida M, Onozuka H, Noguchi M, Mikami T, Kawaguchi H, et al. Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. Am Heart J 1995 130 : 1089 1093.
63. Tesson F, Dufour C, Moolman JC, Carrier L, al-Mahdawi S, Chojnowska L, Dubourg O, et al. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol 1997 29 : 831 838.
64. Ortlepp JR, Vosberg HP, Reith S, Ohme F, Mahon NG, Schroder D, Klues HG, et al. Genetic polymorphisms in the rennin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: A study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart 2002 87 : 270 275.
65. Doiuchi J, Hamada M, Ito T, Kokubu T. Comparative effects of calcium-channel blockers and beta-adrenergic blocker on early diastolic time intervals and A-wave ratio in patients with hypertrophic cardiomyopathy. Clin Cardiol 1987 10 : 26 30.
66. Lorell BH. Use of calcium channel blockers in hypertrophic cardiomyopathy. Am J Med 1985 78 : 43 54.
67. Moran AM, Colan SD. Verapamil therapy in infants with hypertrophic cardiomyopathy. Cardiol Young 1998 8 : 310 319.
68. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001 38 : 1701 1706. (Pubitemid 33065457)
69. Maron BJ, Dearani JA, Ommen SR, Maron ML, Schaff HV, Gersh BJ, Nishimura RA. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 44 : 2043 2053.
70. O'Rourke RA. Cardiac pacing. An alternative treatment for selected patients with hypertrophic cardiomyopathy and adjunctive therapy for certain patients with dilated cardiomyopathy. Circulation 1999 100 : 786 788.
71. Maron BJ. Appraisal of dual-chamber pacing therapy in hypertrophic cardiomyopathy: Too soon for a rush to judgment? J Am Coll Cardiol 1996 27 : 431 432.
72. Begley D, Mohiddin S, Fananapazir L. Dual chamber pacemaker therapy for mid-cavity obstructive hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2001 24 : 1639 1644.
73. Chang SM, Lakkis NM, Franklin J, Spencer WH III., Nagueh SF. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation 2004 109 : 824 827.
74. Nielsen CD, Killip D, Spencer WH III. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: Short-term results in 50 consecutive procedures. Clin Cardiol 2003 26 : 275 279.
75. Park TH, Lakkis NM, Middleton KJ, Franklin J, Zoghbi WA, Quinones MA, Spencer WH III., et al. Acute effect of nonsurgical septal reduction therapy on regional left ventricular asynchrony in patients with hypertrophic obstructive cardiomyopathy. Circulation 2002 106 : 412 415.
76. Hess OM, Sigwart U. New treatment strategies for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2004 44 : 2054 2055.
77. Cable WJ, Kolodny EH, Adams RD. Fabry disease: Impaired autonomic function. Neurology 1982 32 : 498 502.
78. Sugie K, Yamamoto A, Murayama K, Oh SJ, Takahashi M, Mora M, Riggs JE, et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 2002 58 : 1773 1778.
79. Hers HG, van Hoof F, de Barsy T. Glycogen storage diseases. In : Scriver CR, Beaudet AL, Sly WS, Valle D (eds. The Metabolic Basis of Inherited Disease. 6th Ed. New York, McGraw-Hill, 1989, pp. 425 452.
80. Towbin JA. Molecular genetic aspects of cardiomyopathy. Biochem Med Metab Biol 1993 49 : 283 320.
81. D'Ancona GG, Wurm J, Croce CM. Genetics of type II glycogenosis: Assignment of the human gene for acid α-glucosidase to chromosome 17. Proc Natl Acad Sci USA 1979 76 : 4526 4529.
82. Beratis NG, LaBadie GU, Hirschhorn K. Genetic heterogeneity in acid α-glucosidase deficiency. Am J Hum Genet 1983 35 : 21 33.
83. Zhong N, Martiniuk F, Tzall S, Hirschhorn R. Identification of a missense mutation in one allele of a patient with Pompe disease and use of endonuclease digestion of PCR-amplified RNA to demonstrate lack of mRNA expression from the second allele. Am J Hum Genet 1991 49 : 635 645.
84. Raben N, Danon M, Gilbert AL, Dwivedi S, Collins B, Thurberg BL, Mattaliano RJ, et al. Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 2003 80 : 159 169.
85. Masson C, Cisse I, Simon V, Insalaco P, Audran M. Fabry disease: A review. Joint Bone Spine 2004 71 : 381 383. (Pubitemid 39335671)
86. Colucci WS, Lorell BH, Schoen FJ, Warhol MJ, Grossman W. Hypertrophic obstructive cardiomyopathy due to Fabry's disease. N Engl J Med 1982 307 : 926 928.
87. Becker AE, Schoorl R, Balk AG, van der Heide RM. Cardiac manifestations of Fabry's disease: Report of a case with mitral insufficiency and electrocardiographic evidence of myocardial infarction. Am J Cardiol 1975 36 : 829 835.
88. Goldman ME, Cantor R, Schwartz MF, Baker M, Desnick RJ. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol 1986 7 : 1157 1161.
89. Broadbent JC, Edwards WD, Gordon H, Hartzler GO, Krawisz JE. Fabry cardiomyopathy in the female confirmed by endomyocardial biopsy. Mayo Clin Proc 1981 56 : 623 628.
90. Danon MJ, Oh SJ, DiMauro S, Manaligod JR, Eastwood A, Naidu S, Schliselfeld LH. Lysosomal glycogen storage disease with normal acid maltase. Neurology 1981 31 : 51 57.
91. Nishino I, Fu J, Tanji K, Yamada T, Shimojo S, Koori T, Mora M, et al. Primary LAMP-2 deficiency causes X-linked vascular cardiomyopathy and myopathy (Danon Disease). Nature 2000 406 : 906 909.
92. Charron P, Villard E, Sebillon P, Laforet P, Maisonobe T, Dubosca-Bidot L, Romero N, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: A systematic survey. Heart 90 : 842 846.
93. Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J 2000 346 : 659 669.
94. Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA. Dealing with energy demand: The AMP-activated protein kinase. Trends Biochem Sci 1999 24 : 22 25. (Pubitemid 29074459)
95. Arad M, Moskowitz IP, Patel VV, Ahmad F, Perez-Atayde AR, Sawyer DB, Walter M, et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 2003 107 : 2850 2856.
96. Attardi G. The elucidation of the human mitochondrial genome: A historical perspective. Bioessays 1996 5 : 34 39.
97. Wallace DC, Zheng X, Lott MT, Shoffner JM, Hodge JA, Kelley RI, Epstein CM, et al. Familial mitochondrial encephalomyopathy (MERRF): Genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease. Cell 1988 55 : 601 610.
98. Petty RKH, Harding AE, Morgan-Hughes JA. The clinical features of mitochondrial myopathy. Brain 1986 109 : 915 938.
99. Mariotti C, Tiranti V, Carrara F, Dallapiccola B, DiDonato S, Zeviani M. Defective respiratory capacity and mitochondrial protein synthesis in transformant cybrids harboring the tRNALeu(UUR) mutation associated with maternally inherited myopathy and cardiomyopathy. J Clin Invest 1994 93 : 1102 1107.
100. Vogel H. Mitochondrial myopathies and the role of the pathologist in the molecular era. J Neuropathol Exp Neurol 2001 60 : 217 227.
101. Capaldi RA, Halphen DG, Zhang YZ, Yanamura W. Complexity and tissue specificity of the mitochondrial respiratory chain. J Bioenerg Biomembr 1988 20 : 291 311.
102. Ozawa T, Tanaka M, Sugiyama S, Hattori K, Ito T, Oho K, Takahashi A, et al. Multiple mitochondrial DNA deletions exist in cardiomyocytes of patients with hypertrophic or dilated cardiomyopathy. Biochem Biophys Res Commun 1990 170 : 830 836.
103. Channer KD, Channer JL, Campbell MJ, Rees JR. Cardiomyopathy in Kearns-Sayre syndrome. Br Heart J 1988 59 : 486 490.
104. Chin TK, Perloff JK, Williams RG, Jue K, Mohrmann R. Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation 1990 82 : 507 513.
105. Stollberger C, Finsterer J, Blazek G. Left ventricular hypertrabeculation/ noncompaction and association with additional cardiac abnormalities and neuromuscular disorders. Am J Cardiol 2002 90 : 899 902.
106. Stollberger C, Finsterer J. Left ventricular hypertrabeculation/ noncompaction. J Am Soc Echocardiogr 2004 17 : 91 100.
107. Ichida F, Hamamichi Y, Miyawaki T, Ono Y, Kamiya T, Akagi T, Hamada H, et al. Clinical features of isolated noncompaction of the ventricular myocardium: Long-term clinical course, hemodynamic properties and genetic background. J Am Coll Cardiol 1999 34 : 233 240.
108. Ichida F, Tsubata S, Bowles KR, Haneda N, Uese K, Miyawaki T, Dreyer WJ, et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 2001 103 : 1256 1263.
109. Scaglia F, Towbin JA, Craigen WJ, Belmont JW, Smith EO, Neish SR, Ware SM, et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 2004 114 : 925 931.
110. Vatta M, Mohapatra B, Jimenez S, Sanchez X, Faulkner G, Perles Z, Sinagra G, et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol 2003 42 : 2014 2027.